scholarly journals Survival after Liver Transplantation for Hepatitis C Is Unchanged over Two Decades in Canada

2008 ◽  
Vol 22 (2) ◽  
pp. 153-154 ◽  
Author(s):  
Kymberly DS Watt ◽  
Kelly W Burak ◽  
Marc Deschênes ◽  
Les Lilly ◽  
Denis Marleau ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Cause Of Death ◽  
Survival Rates ◽  
Hcv Infection ◽  
Common Cause ◽  
Allograft Failure ◽  
Survival Difference ◽  
Registry Database

Allograft failure secondary to recurrence of hepatitis C virus (HCV) infection is the most common cause of death and retransplantation among recipients with HCV infection. It has been suggested that patients transplanted for HCV have had worse outcomes in more recent years than in previous years (the ‘era effect’). A Canadian transplantation registry database was analyzed to determine the outcomes of patients transplanted over the years for HCV. The results of the present analysis of 1002 patients show that the ‘era effect’ was not seen in liver transplantation recipients with HCV in Canada, because no survival difference was noted based on the year of transplantation. All groups had overall two-year and five-year survival rates of 76% to 83% and 69% to 72%, respectively. The present study’s national results prove continued benefit to transplantation of HCV patients.

Hepatitis C virus (HCV)-specific CD8+ T cells in patients with recurrent HCV-infection after liver transplantation (OLTx)

2001 ◽  
Vol 34 ◽  
pp. 115
Author(s):  
C.A. Schirren ◽  
N.H. Gruener ◽  
M.C. Jung ◽  
R. Zachoval ◽  
J.T. Gerlach ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
T Cells ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Cd8 T Cells ◽  
Hcv Infection

scholarly journals Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma

2017 ◽  
Vol 11 (3) ◽  
pp. 701-710 ◽  
Author(s):  
Yumiko Nagao ◽  
Kazunori Nakasone ◽  
Tatsuji Maeshiro ◽  
Nao Nishida ◽  
Kanae Kimura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Immunosuppressive Drugs ◽  
Hcv Infection ◽  
Direct Acting ◽  
Oral Lichen

Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF). The 50-year-old patient developed erosive OLP during IFN therapy, with hyperthyroidism at 53 years of age and HCC at 55 years. He received immunosuppressive drugs and IFN-free DAA treatment after liver transplantation at 60 years of age, which led to disappearance of the symptoms of OLP. The patient was treated safely and effectively with LDV/SOF, although it is not known whether the disappearance of OLP resulted from the eradication of HCV or the immunosuppressive therapy.

808 Despite the Declining Prevalence of Hepatitis C Virus (HCV) Infection in the U.S., Rates of HCV-Related Liver Transplantation Continue to Increase, More Than Doubling Among Blacks

2015 ◽  
Vol 148 (4) ◽  
pp. S-997-S-998
Author(s):  
Maria Aguilar ◽  
Harleen K. Dyal ◽  
Benny Liu ◽  
Taft Bhuket ◽  
Zobair M. Younossi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hcv Infection ◽  
The U.S

scholarly journals Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

10.36469/9854 ◽  
2013 ◽  
Vol 1 (1) ◽  
pp. 62-82
Author(s):  
Raymond Odhiambo ◽  
Jagpreet Chhatwal ◽  
Shannon Allen Ferrante ◽  
Antoine El Khoury ◽  
Elamin Elbasha
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Triple Therapy ◽  
Dual Therapy ◽  
Hcv Infection ◽  
Genotype 1 ◽  
Life Years ◽  
Treatment Naïve

Background: Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients chronically infected with genotype 1 hepatitis C virus (HCV) infection. The objective of this study was to evaluate the cost-effectiveness of triple therapy in both treatment-naive and treatment-experienced patients in Hungary. Methods: A Markov model was developed to evaluate the long-term clinical benefits and the costeffectiveness of the triple therapy from the Hungarian payer perspective. Model states were fibrosis (F0–F4, defined using METAVIR fibrosis scores), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), and liver-related deaths (LD). Efficacy was estimated from SPRINT-2 and RESPOND-2 studies. Disease progression rates and health state utilities used in the model were obtained from published studies. Estimates of probability of liver transplantation and cost were based on an analysis of the Hungarian Sick Fund database. All cost and benefits were discounted at 5% per year. Results: Compared to dual therapy, triple therapy was projected to increase the life expectancy by 0.98 and 2.42 life years and increase the quality-adjusted life years (QALY) by 0.59 and 1.13 in treatment-naive and treatment-experienced patients, respectively. The corresponding incremental cost-effectiveness ratios were HUF7,747,962 (€26,717) and HUF5,888,240 (€20,304) per QALY. The lifetime incidence of severe liver disease events (DC, HCC, LT, LD) were projected to decrease by 45% and 61% in treatment-naïve and treatment-experienced patients treated with triple therapy groups in comparison with PEG-RBV treatment. Conclusion: The addition of boceprevir to standard therapy for the treatment of patients with genotype 1 chronic HCV infection in Hungary is projected to be cost-effective using a commonly used willingness to pay threshold of HUF 8.46 million (3 times gross domestic product per capita).

scholarly journals Diagnostic Value of Anti-Hepatitis C Virus (HCV) Core Immunoglobulin M in Recurrence of HCV Infection after Orthotopic Liver Transplantation †

1999 ◽  
Vol 37 (8) ◽  
pp. 2726-2728 ◽  
Author(s):  
Carmela Casino ◽  
Daniela Lilli ◽  
Daniela Rivanera ◽  
Antonella Comanducci ◽  
Massimo Rossi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Orthotopic Liver Transplantation ◽  
Alanine Aminotransferase ◽  
Diagnostic Value ◽  
Immunoglobulin M ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Histological Data

The significance of anti-hepatitis C virus (HCV) core immunoglobulin M (IgM) and its relationship with genotypes, alanine aminotransferase abnormality, and histological data were studied for 18 patients who had undergone orthotopic liver transplantation due to HCV-related end-stage disease. During follow-up, IgM response seemed to be associated with the recurrence of HCV infection but did not correlate with abnormal alanine aminotransferase levels and histological data. In addition, the results of this study indicated that the detection of HCV RNA is critical for diagnosis of reinfection in liver transplantation.

Sign in / Sign up

Export Citation Format

Share Document